StockWatch
·

Alkem Laboratories Ltd Q2 FY27 Results

ALKEMQ2 FY27 Results
Filing
Result:Weak· Market: Down#One-off gain#Margin squeeze#Base effect

Beat/Miss: Beat

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue4.6K21.7%13.8%
Total Income4.7K20.4%14.2%
Expenditure3.7K19.3%16.0%
PBT999.6529.5%11.6%
Net Profit667.1328.1%14.4%
OPM23.29%2.81pp0.28pp
NPM14.24%0.86pp4.74pp
EPS56.4829.9%11.7%
View full financials

Core pharma business was solid (revenue +13.8%, segment EBIT +26%, OPM held above guidance), but adjusted consolidated PAT fell ~19% YoY on a tax-rate normalization and new Occlutech-driven subsidiary losses, so the sector's key adjusted-profit metric was clearly down despite the street beat.

Q2 FY-2027 RESULTS · ALKEM

Alkem Q2FY27: consolidated PAT falls 14% YoY to ₹667 Cr as tax rate resets higher

PAT -14.38% YoY · revenue +13.77% · margins compressing · beat vs street

12 Nov 2026 · 3 min read
Revenue

₹4,551.99 Cr

+13.77% YoY

PAT (consolidated)

₹667.13 Cr

-14.38% YoY

Net margin

14.24%

-4.7pp YoY

EPS

₹56.48

Alkem Laboratories posted consolidated revenue of ₹4,551.99 Cr for Q2 FY27, up 13.77% YoY (and 21.71% QoQ, though the sequential jump isn't fully comparable since Occlutech was consolidated only from 16 July 2026, partway through the prior quarter). Consolidated PAT (profit for the period) fell 14.38% YoY to ₹667.13 Cr; adjusted for a ₹35 Cr one-off investment-recovery gain booked this quarter with no counterpart a year ago, the decline widens to roughly 18.9%. Standalone (parent-only) PAT from continuing operations was ₹762.48 Cr, essentially flat YoY (+5.4% raw, ~+0.5% on the same adjusted basis) — so the consolidated decline is predominantly a tax and subsidiary-loss story rather than a core-business one. Consolidated EPS was ₹56.48 against ₹63.99 a year ago; standalone EPS was ₹63.77.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹4,551.99 Cr+21.7%+13.8%
Expenses₹3,721.55 Cr+19.2%+16%
PAT₹667.13 Cr+28.05%-14.38%
Net margin14.24%+0.9pp-4.7pp
EPS₹56.48+29.9%-11.7%

The operating margin held up better than feared: OPM (EBITDA/revenue) was 22.52% versus a tough 23.01% year-ago base and up from 20.48% in Q1 FY27, clearing management's reiterated FY27 guidance band of 20-21% despite a pre-result warning about paracetamol-API cost inflation roughly doubling input costs. Net margin fell much more sharply, from 18.98% to 14.24% YoY, because the effective tax rate jumped to 33.2% this quarter (32.9% for H1) from an unusually low ~13% a year ago, as the group completes its transition to the Section 115BAA tax regime — broadly consistent with management's own revised FY27 consolidated tax guidance of 30-32% (down from an earlier 35-38% flagged pre-result). By segment, core Pharmaceuticals EBIT grew 26.3% YoY to ₹1,051.88 Cr on revenue of ₹4,347.92 Cr (+11.8%), but Biotech swung to a ₹114.14 Cr loss (from a near-breakeven ₹0.35 Cr) and MedTech's loss widened to ₹49.63 Cr (from ₹6.31 Cr) as Occlutech — bought for a ~₹1,079.76 Cr consideration and adding ₹703.6 Cr of goodwill — had its first near-complete consolidated quarter; NCI absorbed ₹8.21 Cr of the group loss.

₹
4,868.825,070.795,272.755,474.725,676.685,24108-1009-0109-2410-1911-1111-12Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹5,241, down 0.2% over the past month of trading.

₹ Cr
0290.87581.74872.6667.91Q1 FY26rev ₹3,371 Cr779.11Q2 FY26rev ₹4,001 Cr653.03Q3 FY26rev ₹3,737 Cr251.11Q4 FY26rev ₹3,603 Cr520.98Q1 FY27rev ₹3,740 Cr667.13Q2 FY27rev ₹4,552 Cr
Quarterly consolidated PAT, ₹ Crore

For context: PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

What management guided (1 FY-2027 call)
India FY27 ~12% growth (100 bps above market); US mid-to-high single digit, forex-aided; Int'l sustainable double-digit; CDMO breakeven USD 25-30M annualized by FY28; Occlutech ₹400 Cr sales in 8.5 months, 7-8% EBITDA improvement YoY.

— This quarter: met

No public analyst consensus for PAT or revenue was available pre-result, so a direct beat/miss call on the bottom line isn't possible; against the one concrete, checkable pre-result benchmark — the 20-21% FY27 EBITDA-margin band flagged as the quarter's 'central test' amid API inflation and a high year-ago base — the 22.52% print is a beat. The same preview flagged the Daman facility's USFDA OAI status (affecting ~45% of US revenue) as unresolved; separately, the company disclosed on 30 October 2026 that a different API facility inspection closed with zero US FDA observations, an incremental positive that doesn't resolve Daman itself. No company press release/management commentary had been extracted for this filing at the time of this analysis, so framing here draws on the regulatory filing, segment notes and the pre-result analyst preview. The quarter also carried board-approved CEO succession (Dr. Amrut Naik, effective 11 November 2026, his first results call), a new Saudi Arabia JV, and a forensic audit initiated 21 October 2026 over alleged fund misappropriation — none of which register as quantified P&L items in this statement.

  • W1

    FY27 EBITDA margin trajectory vs management's 20-21% guided band (Q2: 22.52%, Q1: 20.48%) amid flagged paracetamol-API cost inflation

  • W2

    FY27 consolidated effective tax rate vs management's revised 30-32% guidance (H1 actual: 32.9%, Q2: 33.2%)

  • W3

    Daman facility USFDA OAI resolution, flagged pre-result as affecting ~45% of US revenue, still unresolved as of this filing (a separate API facility inspection on 30-Oct-2026 closed with zero observations)

Figures in ₹ Million in source (÷10 to Cr); consolidated PAT (₹667.13 Cr, 'profit for the period') includes NCI drag from newly-consolidated Occlutech (55% stake, acquired 16-Jul-2026, loss-making) and a Biotech swing to loss, while owners'-share PAT is higher at ₹675.34 Cr; standalone PAT is continuing-operations only (no discontinued ops this quarter, unlike year-ago which had the then-recent Generic-business transfer); a ₹35 Cr exceptional gain (investment recovery) appears in both statements this quarter only, with none in the year-ago quarter; consolidated PBT−tax leaves a ₹0.6 Cr gap matching the share of associate loss, standalone ties out exactly.

Informational and educational content only. Not investment advice.